Tag Archives: Peter Lawson

Epizyme Receives a Buy from SunTrust Robinson

In a report released yesterday, Peter Lawson from SunTrust Robinson reiterated a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $20. The company’s shares closed yesterday at $15.30. According to TipRanks.com, Lawson is a 5-star analyst with

NewLink was Downgraded to a Hold Rating at SunTrust Robinson

NewLink (NASDAQ: NLNK) received a Hold rating and a $5 price target from SunTrust Robinson analyst Peter Lawson today. The company’s shares closed on Friday at $4.20, close to its 52-week low of $3.95. According to TipRanks.com, Lawson is a

SunTrust Robinson Thinks Incyte Corp’s Stock is Going to Recover

SunTrust Robinson analyst Peter Lawson reiterated a Buy rating on Incyte Corp (NASDAQ: INCY) yesterday and set a price target of $80. The company’s shares closed yesterday at $64.02, close to its 52-week low of $63.43. According to TipRanks.com, Lawson

SunTrust Robinson Believes Crispr Therapeutics AG (NASDAQ: CRSP) Won’t Stop Here

In a report released yesterday, Peter Lawson from SunTrust Robinson reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ: CRSP), with a price target of $65. The company’s shares closed yesterday at $53.70, close to its 52-week high of $54.89.

SunTrust Robinson Remains a Buy on Array Biopharma

In a report released today, Peter Lawson from SunTrust Robinson reiterated a Buy rating on Array Biopharma (NASDAQ: ARRY), with a price target of $20. The company’s shares opened today at $14.50. According to TipRanks.com, Lawson is a 5-star analyst

MacroGenics Gets a Buy Rating from SunTrust Robinson

In a report released yesterday, Peter Lawson from SunTrust Robinson reiterated a Buy rating on MacroGenics (NASDAQ: MGNX), with a price target of $31. The company’s shares closed yesterday at $20.25. According to TipRanks.com, Lawson is a 5-star analyst with